Tarsus Pharmaceuticals (TARS) Aktievy
Tarsus Pharmaceuticals, Inc. är ett biofarmaceutiskt företag i kommersiell fas som fokuserar på utveckling och kommersialisering av läkemedelskandidater för ögonvård i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
TARS Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 64.4% undervärderad intrinsisk rabatt
5419.8%Revenue growth p.a.
6.2k
18
0
128
Tarsus Pharmaceuticals, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$63.62 |
| 52 veckors högsta | US$85.25 |
| 52 veckors lägsta | US$38.51 |
| Beta | 0.63 |
| 1 månads förändring | -9.27% |
| 3 månaders förändring | -3.50% |
| 1 års förändring | 34.33% |
| 3 års förändring | 314.46% |
| 5 års förändring | 112.21% |
| Förändring sedan börsintroduktionen | 209.14% |
Senaste nyheter och uppdateringar
TARS: Lyme Prevention Pipeline Progress Will Support Stronger Long Term Outlook
Analysts have adjusted their price target on Tarsus Pharmaceuticals to reflect a shift in fair value from $87.50 to about $95.11, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Tarsus began dosing participants in the Phase 2 Calliope trial of TP-05, an oral therapy being evaluated to potentially prevent Lyme disease by killing infected ticks before transmission, with a planned enrollment of about 700 healthy adults across U.S. regions where Lyme is common (Key Developments).Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses
Apr 14
TARS: Lyme Prevention Program And China Milestone Will Support Future Upside
Analysts have raised their fair value estimate for Tarsus Pharmaceuticals from $100.00 to $105.00, reflecting updated assumptions regarding future revenue growth, profit margins, and a higher expected future P/E multiple. What's in the News Tarsus dosed the first participant in the Phase 2 Calliope trial of TP-05, an oral therapy designed to potentially prevent Lyme disease by killing infected ticks before transmission.Recent updates
TARS: Lyme Prevention Pipeline Progress Will Support Stronger Long Term Outlook
Analysts have adjusted their price target on Tarsus Pharmaceuticals to reflect a shift in fair value from $87.50 to about $95.11, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Tarsus began dosing participants in the Phase 2 Calliope trial of TP-05, an oral therapy being evaluated to potentially prevent Lyme disease by killing infected ticks before transmission, with a planned enrollment of about 700 healthy adults across U.S. regions where Lyme is common (Key Developments).Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses
Apr 14TARS: Lyme Prevention Program And China Milestone Will Support Future Upside
Analysts have raised their fair value estimate for Tarsus Pharmaceuticals from $100.00 to $105.00, reflecting updated assumptions regarding future revenue growth, profit margins, and a higher expected future P/E multiple. What's in the News Tarsus dosed the first participant in the Phase 2 Calliope trial of TP-05, an oral therapy designed to potentially prevent Lyme disease by killing infected ticks before transmission.
TARS: China Milestone And Margin Outlook Will Support Future Upside
Narrative Update: Tarsus Pharmaceuticals Analyst Price Target Shift Analysts have kept their $88.00 price target for Tarsus Pharmaceuticals steady while updating their models to reflect projected revenue growth of about 30% and a small improvement in expected profit margins, alongside a modestly lower future P/E assumption. Together, these adjustments indicate fine tuning of expectations rather than a change in the overall view.TARS: Higher Fair Value And Future P/E Will Support Upside
Analysts have lifted their price target for Tarsus Pharmaceuticals from about $60.06 to $88.00, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the key drivers behind the change. Valuation Changes Fair value was raised from about $60.06 to $88.00, suggesting a higher assessed equity value for Tarsus Pharmaceuticals.TARS: Higher Earnings Power And Lower Future P/E Will Support Upside
Analysts have adjusted their price target on Tarsus Pharmaceuticals to reflect updated assumptions for revenue growth of about 47.48%, profit margin of about 45.30% and a future P/E of about 9.89x. Together, these factors point to a meaningfully different view on the stock's earnings power under current models.TARS: Higher Future P/E Assumptions Will Support A More Optimistic Outlook
Analysts have increased their price target for Tarsus Pharmaceuticals from US$92.00 to US$100.00, citing updated assumptions around long term revenue growth, profit margins, and a higher future P/E multiple in their valuation work. Valuation Changes Fair Value: Updated from US$92.00 to US$100.00, reflecting a higher assessed equity value per share.Shareholders Should Be Pleased With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price
Feb 06
TARS: Revenue Guidance And Rich Multiple Will Likely Overstate Future Upside
Analysts now see a slightly lower fair value for Tarsus Pharmaceuticals at about US$60.06 per share, down from roughly US$60.99. This reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E.Does Tarsus Pharmaceuticals (NASDAQ:TARS) Have A Healthy Balance Sheet?
Jan 15TARS: Elevated Profit Assumptions Will Likely Overstate Future Earnings Power
Analysts have lifted their price target on Tarsus Pharmaceuticals from about $49.58 to roughly $60.99, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Tarsus Pharmaceuticals issued full year 2025 revenue guidance in the range of $440 million to $445 million.TARS: Future Revenue Guidance And Margins Will Support Balanced Long-Term Outlook
Analysts have modestly reaffirmed their outlook on Tarsus Pharmaceuticals, maintaining the fair value estimate at approximately 87.50 dollars. They continue to anticipate robust, high margin revenue growth supported by strong, long term fundamentals.TARS: Future Revenue Guidance And Margins Will Support Balanced Long-Term Outlook
Analysts have modestly raised their price target on Tarsus Pharmaceuticals to approximately $88 per share from about $86, citing slightly improved fair value estimates driven by updated assumptions for long term revenue growth, profit margins, and valuation multiples. What's in the News Issued new full-year 2025 revenue guidance, projecting annual revenue of $440 million to $445 million, based on company guidance about anticipated commercial performance.TARS: Future Revenue Momentum And Margin Shifts Will Support Stable Long-Term Outlook
Analysts have raised their price target for Tarsus Pharmaceuticals, increasing the estimated fair value from $84.25 to $86.11. This change is based on improved expectations for revenue growth, even as other key financial assumptions were adjusted.TARS: Future Profit Margin Expansion Will Drive Stronger Financial Performance
Analysts have raised their price target for Tarsus Pharmaceuticals from $80.38 to $84.25, citing improved profit margin forecasts and a more favorable valuation outlook. What's in the News Tarsus Pharmaceuticals has issued new corporate guidance for the fourth quarter of 2025, predicting annual revenue in the range of $440 million to $445 million (Key Developments).TARS: Rising Margins And Patient Demand Will Drive Future Outperformance
Analysts have raised their price target on Tarsus Pharmaceuticals from $78.38 to $80.38, citing expectations for stronger revenue growth and improved profit margins. Valuation Changes Fair Value has increased from $78.38 to $80.38.Market Participants Recognise Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Revenues Pushing Shares 41% Higher
Oct 18Broad Patient Adoption And Global Expansion Will Open Long-Term Opportunities
Analysts have increased their price target for Tarsus Pharmaceuticals, raising the estimated fair value from $76.00 to $78.38. This adjustment is based on updated financial projections and ongoing confidence in the company's growth prospects.Broad Patient Adoption And Global Expansion Will Open Long-Term Opportunities
With both Tarsus Pharmaceuticals’ future P/E ratio (19.91x) and net profit margin (27.99%) remaining stable, there is no shift in analyst sentiment or valuation, and the consensus analyst price target is unchanged at $76.00. What's in the News Dropped from Russell Microcap Growth Benchmark Index Dropped from Russell 3000E Growth Benchmark Dropped from Russell 3000E Index Dropped from Russell Microcap Index Dropped from Russell 3000E Growth Index Valuation Changes Summary of Valuation Changes for Tarsus Pharmaceuticals The Consensus Analyst Price Target remained effectively unchanged, at $76.00.Why Investors Shouldn't Be Surprised By Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) P/S
Jul 30Expanding Ocular And Parasitic Markets Will Drive Future Value
Strong growth driven by expanding XDEMVY adoption, a broader addressable market, favorable demographics, and new indications and geographies diversifying revenue streams.With Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) It Looks Like You'll Get What You Pay For
Apr 02Tarsus Pharma: Strong Execution In Xdemvy Commercialization
Mar 11Is Tarsus Pharmaceuticals (NASDAQ:TARS) Using Too Much Debt?
Feb 07Tarsus: Promising Investment, But Timing Is The Key
Jan 23Tarsus Pharmaceuticals: Early Rollout Exceeding Expectations
Dec 10US$65.33 - That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results
Nov 16Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%
Nov 07Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money
Nov 05Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable
Sep 05Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
Aug 20With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For
Jun 26Following Up On Tarsus Pharmaceuticals
May 28Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results
May 11Aktieägarnas avkastning
| TARS | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | 3.5% | 3.4% | 0.8% |
| 1Y | 34.3% | 27.1% | 27.8% |
Avkastning vs industri: TARS översteg US Pharmaceuticals branschen som gav 27.1 % under det senaste året.
Avkastning vs Marknaden: TARS översteg US marknaden som gav 27.8 % under det senaste året.
Prisvolatilitet
| TARS volatility | |
|---|---|
| TARS Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: TARS har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: TARS s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2016 | 370 | Bobby Azamian | tarsusrx.com |
Tarsus Pharmaceuticals, Inc. är ett biofarmaceutiskt företag i kommersiell fas som fokuserar på utveckling och kommersialisering av läkemedelskandidater för ögonvård i USA. Företaget erbjuder XDEMVY, en oftalmisk lösning med lotilaner för behandling av demodexblefarit som orsakas av demodexkvalster. Företaget säljer sina produkter till specialiserade apotek och distributörer samt till kliniker, sjukhus, apotek och federala hälsovårdsprogram.
Tarsus Pharmaceuticals, Inc. Sammanfattning av grunderna
| TARS grundläggande statistik | |
|---|---|
| Börsvärde | US$2.71b |
| Vinst(TTM) | -US$66.42m |
| Intäkter(TTM) | US$451.36m |
6.0x
P/S-förhållande-40.8x
P/E-förhållandeÄr TARS övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| TARS resultaträkning (TTM) | |
|---|---|
| Intäkter | US$451.36m |
| Kostnad för intäkter | US$95.01m |
| Bruttovinst | US$356.35m |
| Övriga kostnader | US$422.77m |
| Intäkter | -US$66.42m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
May 06, 2026
| Vinst per aktie (EPS) | -1.56 |
| Bruttomarginal | 78.95% |
| Nettovinstmarginal | -14.72% |
| Skuld/egenkapitalförhållande | 21.1% |
Hur har TARS utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/03 21:24 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Tarsus Pharmaceuticals, Inc. bevakas av 20 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jenna Davidner | Barclays |
| Jason Matthew Gerberry | BofA Global Research |
| Andrea Newkirk | Goldman Sachs |